PneumoMab

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NamePneumoMab

Drug Alias Namefully human IgG antibodies (Pamlico Therapeutics)fully human IgG monoclonal antibodies (Pamlico Biopharma)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody

Mechanisms of ActionImmunoglobulin G modulators

TargetsImmunoglobulin G

Therapy Area/IndicationsPneumococcal Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesPamlico BioPharma Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesPamlico BioPharma Inc

Active IndicationsN/A

Inactive IndicationsPneumococcal Infections

Other Information

ATC CodeN/A